Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that its new drug application for sacituzumab tirumotecan, a treatment for advanced non-small cell lung cancer, has been accepted by China’s National Medical Products Administration. This drug, showing promising results in clinical trials, targets solid tumors and has been prioritized for review. The company has licensed rights to commercialize the drug outside Greater China to Merck & Co., Inc.
For further insights into HK:6990 stock, check out TipRanks’ Stock Analysis page.